Organisation paid for research Program year 2025 Source: CMS Open Payments

Asante, Dba Asante Rogue Regional

Neither a doctor nor a teaching hospital

Research payments

$309,232

18 payments

Through program year 2025, Asante, Dba Asante Rogue Regional is reported as receiving $309,232 in research payments, across 18 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$4,584	1
2024	Research	$24,191	6
2022	Research	$60,261	4
2021	Research	$47,673	4
2020	Research	$52,066	1
2019	Research	$120,457	2

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $309,232 18 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $215,070 10 payments
A Phase 1A/1B Study of Ly3484356 Administered As Monotherapy and in Combination With Abemaciclib to Patients With Er+, Her2- Locally Advanced Or Metastatic Breast Cancer $76,599 5 payments
Sunray-01 A Global Pivotal Study in Participants With Kras G12c-Mutant Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Comparing First Line Treatment of Ly3537982 and Pembrolizumab VS Placebo and Pembrolizumab in Those With PD L1 Expression 50% Or Ly3537982 and Pembrolizumab Pemetrexed Platinum VS Placebo and Pembrolizumab Pemetrexed Platinum Regardless of Pd-L1 Expression $17,553 2 payments
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) $9 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.